Angiotensin-converting enzyme and the tumor microenvironment: Mechanisms beyond angiogenesis

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 305, Issue 3, 2013, Pages

  Okwan Duodu, Derick ^a   Landry, Jerome ^a   Shen, Xiao Z ^b   Diaz, Roberto ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Angiotensin converting enzyme; Cancer; Macrophage polarization; Myeloid derived suppressor cells; T regulatory cells; Tumor immunology

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEPTIDE; SERASPENIDE; SUBSTANCE P;

ANGIOGENESIS; BONE MARROW CELL; CARCINOGENESIS; ENZYME INHIBITION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REGULATORY T LYMPHOCYTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; VASCULAR SMOOTH MUSCLE;

ANGIOGENESIS; ANGIOTENSIN-CONVERTING ENZYME; CANCER; MACROPHAGE POLARIZATION; MYELOID-DERIVED SUPPRESSOR CELLS; T REGULATORY CELLS; TUMOR IMMUNOLOGY;

ANIMALS; HUMANS; MYELOID CELLS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84880998463     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00544.2012     Document Type: Review

References (157)

1. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404: 193-197, 2000.
2. Aki K, Shimizu A, Masuda Y, Kuwahara N, Arai T, Ishikawa A, Fujita E, Mii A, Natori Y, Fukunaga Y, Fukuda Y. ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol 298: F870-F882, 2010.
3. Aliberti J, Viola JP, Vieira-de-Abreu A, Bozza PT, Sher A, Scharfstein J. Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J Immunol 170: 5349-5353, 2003.
4. Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J Gastrointest Surg 12: 57-66, 2008.
5. Andoh T, Akira A, Saiki I, Kuraishi Y. Bradykinin increases the secretion and expression of endothelin-1 through kinin B2 receptors in melanoma cells. Peptides 31: 238-241, 2010.
6. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 29: 623-635, 2011.
7. Ardaillou R. Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Curr Opin Nephrol Hypertens 6: 28-34, 1997.
8. Ardaillou R, Chansel D. Synthesis and effects of active fragments of angiotensin II. Kidney Int 52: 1458-1468, 1997.
9. Azizi M, Ezan E, Nicolet L, Grognet JM, Menard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 30: 1015-1019, 1997.
10. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97: 839-844, 1996.
11. Balyasnikova IV, Danilov SM, Muzykantov VR, Fisher AB. Modu lation of angiotensin-converting enzyme in cultured human vascular endothelial cells. In Vitro Cell Dev Biol Anim 34: 545-554, 1998.
12. Balyasnikova IV, Sun ZL, Metzger R, Taylor PR, Vicini E, Muciaccia B, Visintine DJ, Berestetskaya YV, McDonald TD, Danilov SM. Monoclonal antibodies to native mouse angiotensin-converting enzyme (CD143): ACE expression quantification, lung endothelial cell targeting and gene delivery. Tissue Antigens 67: 10-29, 2006.
13. Barisione C, Garibaldi S, Ghigliotti G, Fabbi P, Altieri P, Casale MC, Spallarossa P, Bertero G, Balbi M, Corsiglia L, Brunelli C. CD14CD16 monocyte subset levels in heart failure patients. Dis Markers 28: 115-124, 2010.
14. Basak GW, Yasukawa S, Alfaro A, Halligan S, Srivastava AS, Min WP, Minev B, Carrier E. Human embryonic stem cells hemangioblast express HLA-antigens. J Transl Med 7: 27, 2009.
15. Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 23: 317-329, 2004.
16. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nature Rev Cancer 3: 401-410, 2003.
17. Bernstein KE. Views of the renin-angiotensin system: brilling, mimsy, and slithy tove. Hypertension 47: 509-514, 2006.
18. Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, Gonzalez-Villalobos RA, Shen XZ, Fuchs S, Touyz RM. A modern understanding of the traditional and nontraditional biological functions of Angiotensin-converting enzyme. Pharmacol Rev 65: 1-46, 2013.
19. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265, 2002.
20. Borkowski JA, Ransom RW, Seabrook GR, Trumbauer M, Chen H, Hill RG, Strader CD, Hess JF. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270: 13706-13710, 1995.
21. Bras G, Bochenska O, Rapala-Kozik M, Guevara-Lora I, Faussner A, Kozik A. Extracellular aspartic protease SAP2 of Candida albicans yeast cleaves human kininogens and releases proinflammatory peptides, Met-Lys-bradykinin and des-Arg(9)-Met-Lys-bradykinin. Biol Chem 393: 829-839, 2012.
22. Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. Targeting regula-tory T cells in cancer. Cancer Res 71: 6915-6920, 2011
23. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438: 932-936, 2005.
24. Cascieri MA, Bull HG, Mumford RA, Patchett AA, Thornberry NA, Liang T. Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422. Mol Pharmacol 25: 287-293, 1984.
25. Castro TA, Cohen MC, Rameshwar P. The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential. Clin Exper Metast 22: 621-628, 2005.
26. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 43: 1140-1145, 2004.
27. Celerier J, Cruz A, Lamande N, Gasc JM, Corvol P. Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 39: 224-228, 2002.
28. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 29: 585-593, 2011.
29. Cole J, Quach DL, Sundaram K, Corvol P, Capecchi MR, Bernstein KE. Mice lacking endothelial angiotensin-converting enzyme have a normal blood pressure. Circ Res 90: 87-92, 2002.
30. Cole JM, Khokhlova N, Sutliff RL, Adams JW, Disher KM, Zhao H, Capecchi MR, Corvol P, Bernstein KE. Mice lacking endothelial ACE: normal blood pressure with elevated angiotensin II. Hypertension 41: 313-321, 2003.
31. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266, 2006.
32. Correa-Noronha SA, Ribeiro de Noronha SM, Alecrim C, Mesquita AD, Brito GS, Junqueira MG, Leite DB, Carvalho CV, Silva ID. Association of angiotensin-converting enzyme I gene I/D polymorphism with endometrial but not with ovarian cancer. Gynecol Endocrinol 28: 889-891, 2012.
33. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, Ryan RJ, Iwamoto Y, Marinelli B, Gorbatov R, Forghani R, Novobrantseva TI, Koteliansky V, Figueiredo JL, Chen JW, Anderson DG, Nahrendorf M, Swirski FK, Weissleder R, Pittet MJ. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA 109: 2491-2496, 2012.
34. Corvol P, Jeunemaitre X, Charru A, Kotelevtsev Y, Soubrier F. Role of the renin-angiotensin system in blood pressure regulation and in human hypertension: new insights from molecular genetics. Recent Prog Horm Res 50: 287-308, 1995.
35. Corvol P, Lamande N, Cruz A, Celerier J, Gasc JM. Inhibition of angiogenesis: a new function for angiotensinogen and des(angiotensin I)angiotensinogen. Curr Hypertens Rep 5: 149-154, 2003.
36. Corvol P, Williams TA, Soubrier F. Peptidyl dipeptidase A: angiotensin I-converting enzyme. Methods Enzymol 248: 283-305, 1995.
37. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 290: 33-40, 1993.
38. Danilov SM, Sadovnikova E, Scharenborg N, Balyasnikova IV, Svinareva DA, Semikina EL, Parovichnikova EN, Savchenko VG, Adema GJ. Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hematol 31: 1301-1309, 2003.
39. Davies JQ, Gordon S. Isolation and culture of murine macrophages. Methods Mol Biol 290: 91-103, 2005.
40. Dutra RC, Leite DF, Bento AF, Manjavachi MN, Patricio ES, Figueiredo CP, Pesquero JB, Calixto JB. The role of kinin receptors in preventing neuroinflammation and its clinical severity during experimental autoimmune encephalomyelitis in mice. PLos One 6: e27875, 2011.
41. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112: 67-75, 2003.
42. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 72: 2162-2171, 2012.
43. Feng F, Yang J, Tong L, Yuan S, Tian Y, Hong L, Wang W, Zhang H. Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells. Cell Biol Int 35: 623-629, 2011.
44. Feng LL, Wang X. Targeting Foxp3 regulatory T cells-related immunosuppression for cancer immunotherapy. Chin Med J (Engl) 123: 3334-3342, 2010.
45. Fernandes PD, Gomes Nde M, Sirois P. The bradykinin B1 receptor antagonist R-954 inhibits Ehrlich tumor growth in rodents. Peptides 32: 1849-1854, 2011.
46. Fernandez-Duenas V, Ciruela F, Gandia J, Sanchez S, Planas E, Poveda R. Histamine H3 receptor activation potentiates peripheral opioid-mediated antinociception: substance P role in peripheral inflammation in mice. Eur J Pharmacol 638: 72-77, 2010.
47. Fleetwood AJ, Dinh H, Cook AD, Hertzog PJ, Hamilton JA. GMCSF-and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J Leukoc Biol 86: 411-421, 2009.
48. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
49. Friedland J, Setton C, Silverstein E. Induction of angiotensin converting enzyme in human monocytes in culture. Biochem Biophys Res Commun 83: 843-849, 1978.
50. Fuchs S, Xiao HD, Cole JM, Adams JW, Frenzel K, Michaud A, Zhao H, Keshelava G, Capecchi MR, Corvol P, Bernstein KE. Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem 279: 15946-15953, 2004.
51. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26: 271-279, 2005.
52. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, Miyaguchi S, Qiang XL, Sakata Y, Nakazawa T, Ikehata F, Ohta S, Toyota T. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 36: 49-55, 1997.
53. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174, 2009.
54. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nature Rev Cancer 10: 745-759, 2010.
55. Gobel K, Pankratz S, Schneider-Hohendorf T, Bittner S, Schuhmann MK, Langer HF, Stoll G, Wiendl H, Kleinschnitz C, Meuth SG. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. J Autoimmun 36: 106-114, 2011.
56. Gonzalez-Zuloeta Ladd AM, Arias Vasquez A, Sayed-Tabatabaei FA, Coebergh JW, Hofman A, Njajou O, Stricker B, van Duijn C. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14: 2143-2146, 2005.
57. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Froland SS, Fowler M. Effect of highversus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 34: 2061-2067, 1999.
58. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460, 2007.
59. Hagiwara S, Iwasaka H, Matumoto S, Hidaka S, Noguchi T. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models. Crit Care Med 37: 626-633, 2009.
60. Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L. Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. Br J Cin Pharmacol 74: 180-188, 2012.
61. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
62. Harrison DG, Guzik TJ. Studies of the T-cell angiotensin receptor using cre-lox technology: an unan-T-cellpated result. Circ Res 110: 1543-1545, 2012.
63. Hasanzad M, Samzadeh M, Jamaldini SH, Haghdoost AA, Afshari M, Ziaei SA. Association of angiotensin I converting enzyme polymorphism as genetic risk factor in benign prostatic hyperplasia and prostate cancer. Genet Test Mol Biomarkers 16: 770-774, 2012.
64. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, Wulff C. Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol 109: 418-425, 2008.
65. Himes SR, Tagoh H, Goonetilleke N, Sasmono T, Oceandy D, Clark R, Bonifer C, Hume DA. A highly conserved c-fms gene intronic element controls macrophage-specific and regulated expression. J Leukoc Biol 70: 812-820, 2001.
66. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 296: R208-R216, 2009.
67. Hooper NM, Kenny AJ, Turner AJ. The metabolism of neuropeptides. Neurokinin A (substance K) is a substrate for endopeptidase-2411 but not for peptidyl dipeptidase A (angiotensin-converting enzyme). Biochem J 231: 357-361, 1985.
68. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. Gr-1 CD115 immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131, 2006.
69. Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood 120: 3030-3038, 2012.
70. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos EG. Activation of bradykinin B1 receptor by ACE inhibitors. Int Immunopharmacol 2: 1787-1793, 2002.
71. Jethon A, Pula B, Piotrowska A, Wojnar A, Rys J, Dziegiel P, Podhorska-Okolow M. Angiotensin II type 1 receptor (AT-1R) expression correlates with VEGF-A and VEGF-D expression in invasive ductal breast cancer. Pathol Oncol Res 18: 867-873, 2012.
72. Jokubaitis VJ, Sinka L, Driessen R, Whitty G, Haylock DN, Bertoncello I, Smith I, Peault B, Tavian M, Simmons PJ. Angiotensinconverting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood 111: 4055-4063, 2008.
73. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature Rev Cancer 9: 239-252, 2009.
74. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev Cancer 2: 727-739, 2002.
75. Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Shin SW, Kim YH. How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology 83: 354-360, 2012.
76. Kohlstedt K, Busse R, Fleming I. Signaling via the angiotensinconverting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension 45: 126-132, 2005.
77. Kohlstedt K, Shoghi F, Muller-Esterl W, Busse R, Fleming I. CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ Res 91: 749-756, 2002.
78. Kohlstedt K, Trouvain C, Namgaladze D, Fleming I. Adipocytederived lipids increase angiotensin-converting enzyme (ACE) expression and modulate macrophage phenotype. Basic Res Cardiol 106: 205-215, 2011.
79. Lazarus DS, Aschoff J, Fanburg BL, Lanzillo JJ. Angiotensin converting enzyme (kininase II) mRNA production and enzymatic activity in human peripheral blood monocytes are induced by GM-CSF but not by other cytokines. Biochim Biophys Acta 1226: 12-18, 1994.
80. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci USA 86: 779-782, 1989.
81. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352: 179-184, 1998.
82. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236-241, 1990.
83. Lin C, Datta V, Okwan-Duodu D, Chen X, Fuchs S, Alsabeh R, Billet S, Bernstein KE, Shen XZ. Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB J 25: 1145-1155, 2011.
84. Liu JM, Bignon J, Ilic V, Briscoe C, Lallemand JY, Riches A, Wdzieczak-Bakala J. Evidence for an association of high levels of endogenous Acetyl-Ser-Asp-Lys-Pro, a potent mediator of angiogenesis, with acute myeloid leukemia development. Leuk Lymphoma 47: 1915-1920, 2006.
85. Liu JM, Garcia-Alvarez MC, Bignon J, Kusinski M, Kuzdak K, Riches A, Wdzieczak-Bakala J. Overexpression of the natural tetrapeptide acetyl-N-ser-asp-lys-pro derived from thymosin beta4 in neoplastic diseases. Ann NY Acad Sci 1194: 53-59, 2010.
86. Liu JM, Gora-Tybor J, Grzybowska-Izydorczyk O, Bignon J, Robak T, Wdzieczak-Bakala J. Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies. Leuk Lymphoma 50: 2096-2097, 2009.
87. Ma T, Liu L, Wang P, Xue Y. Evidence for involvement of ROCK signaling in bradykinin-induced increase in murine blood-tumor barrier permeability. J Neurooncol 106: 291-301, 2012.
88. Maeda A, Okazaki T, Inoue M, Kitazono T, Yamasaki M, Lemonnier FA, Ozaki S. Immunosuppressive effect of angiotensin receptor blocker on stimulation of mice CTLs by angiotensin II. Int Immunopharmacol 9: 1183-1188, 2009.
89. Malonne H, Langer I, Kiss R, Atassi G. Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Clin Exp Metast 17: 1-14, 1999.
90. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumorassociated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 70: 325-330, 2009.
91. Mayordomo C, Garcia-Recio S, Ametller E, Fernandez-Nogueira P, Pastor-Arroyo EM, Vinyals L, Casas I, Gascon P, Almendro V. Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2. J Cell Physiol 227: 1358-1366, 2012.
92. Montana V, Sontheimer H. Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci 31: 4858-4867, 2011.
93. Mulay SR, Gaikwad AB, Tikoo K. Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. Chemico Biol Interact 185: 137-142, 2010.
94. Munoz M, Bernabeu-Wittel J, Covenas R. NK-1 as a melanoma target. Expert Opin Ther Targets 15: 889-897, 2011.
95. Munoz M, Rosso M, Aguilar FJ, Gonzalez-Moles MA, Redondo M, Esteban F. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 26: 111-118, 2008.
96. Munoz M, Rosso M, Covenas R. The NK-1 receptor: a new target in cancer therapy. Curr Drug Targets 12: 909-921, 2011.
97. Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C, Piruat JI. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39: 427-432, 2005.
98. Munoz M, Rosso M, Robles-Frias MJ, Salinas-Martin MV, Rosso R, Gonzalez-Ortega A, Covenas R. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 90: 1259-1269, 2010.
99. Myohanen TT, Tenorio-Laranga J, Jokinen B, Vazquez-Sanchez R, Moreno-Baylach MJ, Garcia-Horsman JA, Mannisto PT. Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. Br J Pharmacol 163: 1666-1678, 2011.
100. Nakagawa P, Liu Y, Liao TD, Chen X, Gonzalez GE, Bobbitt KR, Smolarek D, Peterson EL, Kedl R, Yang XP, Rhaleb NE, Carretero OA. Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in rats. Am J Physiol Heart Circ Physiol 303: H1114-H1127, 2012.
101. Nakai Y, Isayama H, Ijichi H, Sasaki T, Kogure H, Yagioka H, Miyabayashi K, Mizuno S, Yamamoto K, Mouri D, Kawakubo K, Yamamoto N, Hirano K, Sasahira N, Tateishi K, Tada M, Koike K. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Cancer Sci 103: 1489-1492, 2012.
102. Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y, Mizuno S, Yamamoto K, Arizumi T, Togawa O, Matsubara S, Tsujino T, Tateishi K, Tada M, Omata M, Koike K. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103: 1644-1648, 2010.
103. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 104: 1693-1701, 1999.
104. Ohnuma Y, Toda M, Fujita M, Hosono K, Suzuki T, Ogawa Y, Amano H, Kitasato H, Hayakawa K, Majima M. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed Pharmacother 63: 136-145, 2009.
105. Okwan-Duodu D, Datta V, Shen XZ, Goodridge HS, Bernstein EA, Fuchs S, Liu GY, Bernstein KE. Angiotensin-converting enzyme overexpression in mouse myelomonocytic cells augments resistance to Listeria and methicillin-resistant Staphylococcus aureus. J Biol Chem 285: 39051-39060, 2010.
106. Oliveira CR, Paredes-Gamero EJ, Barbosa CM, Nascimento FD, Batista EC, Reis FC, Martins AH, Ferreira AT, Carmona AK, Pesquero JB, Tersariol IL, Araujo RC, Bincoletto C. Myelopoiesis modulation by ACE hyperfunction in kinin B(1) receptor knockout mice: relationship with AcSDKP levels. Chemico Biol Interact 184: 388-395, 2010.
107. Ong FS, Lin CX, Campbell DJ, Okwan-Duodu D, Chen X, Blackwell WL, Shah KH, Gonzalez-Villalobos RA, Shen XZ, Fuchs S, Bernstein KE. Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity. Hypertension 59: 283-290, 2012.
108. Otake AH, Mattar AL, Freitas HC, Machado CM, Nonogaki S, Fujihara CK, Zatz R, Chammas R. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol 66: 79-87, 2010.
109. Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets 7: 1043-1052, 2006.
110. Pedroza-Gonzalez A, Verhoef C, Ijzermans JN, Peppelenbosch MP, Kwekkeboom J, Verheij J, Janssen HL, Sprengers D. Activated tumor-infiltrating CD4 regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 57: 183-194, 2012.
111. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22: 238-244, 2010.
112. Piastowska-Ciesielska AW, Pluciennik E, Wojcik-Krowiranda K, Bienkiewicz A, Bednarek A, Ochedalski T. Analysis of the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics. Tumour Biol 33: 767-774, 2012.
113. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1-and TH17-mediated autoimmunity. Proc Natl Acad Sci USA 106: 14948-14953, 2009.
114. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51, 2010.
115. Rameshwar P, Poddar A, Gascon P. Hematopoietic regulation mediated by interactions among the neurokinins and cytokines. Leuk Lymphoma 28: 1-10, 1997.
116. Rasini E, Cosentino M, Marino F, Legnaro M, Ferrari M, Guasti L, Venco A, Lecchini S. Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. Regul Pept 134: 69-74, 2006.
117. Raymond P, Drapeau G, Raut R, Audet R, Marceau F, Ong H, Adam A. Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. J Immunol Methods 180: 247-257, 1995.
118. Richard DE, Vouret-Craviari V, Pouyssegur J. Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene 20: 1556-1562, 2001.
119. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346, 1990.
120. Rosso M, Robles-Frias MJ, Covenas R, Salinas-Martin MV, Munoz M. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol 29: 245-254, 2008.
121. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, Miyake T, Matsushita K, Okazaki T, Saitoh T, Honma K, Matsuyama T, Yui K, Tsujimura T, Standley DM, Nakanishi K, Nakai K, Akira S. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nature Immunol 11: 936-944, 2010.
122. Savary K, Michaud A, Favier J, Larger E, Corvol P, Gasc JM. Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo. Blood 105: 103-110, 2005.
123. Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 109: 1007-1009, 2002.
124. Shen XZ, Bernstein KE. The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis. Cell Cycle 10: 1363-1369, 2011.
125. Shen XZ, Billet S, Lin C, Okwan-Duodu D, Chen X, Lukacher AE, Bernstein KE. The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nature Immunol 12: 1078-1085, 2011.
126. Shen XZ, Li P, Weiss D, Fuchs S, Xiao HD, Adams JA, Williams IR, Capecchi MR, Taylor WR, Bernstein KE. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am J Pathol 170: 2122-2134, 2007.
127. Shen XZ, Ong FS, Bernstein EA, Janjulia T, Blackwell WL, Shah KH, Taylor BL, Gonzalez-Villalobos RA, Fuchs S, Bernstein KE. Nontraditional roles of angiotensin-converting enzyme. Hypertension 59: 763-768, 2012.
128. Shi RZ, Wang JC, Huang SH, Wang XJ, Li QP. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp Cell Res 315: 10-15, 2009.
129. Shibata K, Kikkawa F, Mizokami Y, Kajiyama H, Ino K, Nomura S, Mizutani S. Possible involvement of adipocyte-derived leucine aminopeptidase via angiotensin II in endometrial carcinoma. Tumour Biol 26: 9-16, 2005.
130. Silva-Filho JL, Souza MC, Henriques MG, Morrot A, Savino W, Nunes MP, Caruso-Neves C, Pinheiro AA. AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes. Mol Immunol 48: 1835-1843, 2011.
131. Sipahi I, Chou J, Mishra P, Debanne SM, Simon DI, Fang JC. Meta-analysis of randomized controlled trials on effect of angiotensinconverting enzyme inhibitors on cancer risk. Am J Cardiol 108: 294-301, 2011.
132. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomized controlled trials. Lancet Oncol 11: 627-636, 2010.
133. Spector TD, Thompson SG. The potential and limitations of metaanalysis. J Epidemiol Commun Health 45: 89-92, 1991.
134. Stegbauer J, Lee DH, Seubert S, Ellrichmann G, Manzel A, Kvakan H, Muller DN, Gaupp S, Rump LC, Gold R, Linker RA. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci USA 106: 14942-14947, 2009.
135. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362: 875-885, 2010.
136. Stewart JM. Bradykinin antagonists as anti-cancer agents. Curr Pharmaceut Design 9: 2036-2042, 2003.
137. Stoll M, Meffert S, Stroth U, Unger T. Growth or antigrowth: angiotensin and the endothelium. J Hypertens 13: 1529-1534, 1995.
138. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95: 651-657, 1995.
139. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, Kikkawa F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 11: 2686-2694, 2005.
140. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325: 612-616, 2009.
141. Tavian M, Biasch K, Sinka L, Vallet J, Peault B. Embryonic origin of human hematopoiesis. Int J Dev Biol 54: 1061-1065, 2010.
142. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251, 1993.
143. Tuluc F, Lai JP, Kilpatrick LE, Evans DL, Douglas SD. Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol 30: 271-276, 2009.
144. Ulrich C, Seibert E, Heine GH, Fliser D, Girndt M. Monocyte angiotensin converting enzyme expression may be associated with atherosclerosis rather than arteriosclerosis in hemodialysis patients. Clin J Am Soc Nephrol 6: 505-511, 2011.
145. van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 112: 748-757, 2008.
146. Vinson GP, Barker S, Puddefoot JR. The renin-angiotensin system in the breast and breast cancer. Endocr Relat Cancer 19: R1-R19, 2012.
147. Wang Q, Lei X, Zhu S, Zhang S. Angiotensin-I converting enzyme inhibitors suppress angiogenesis and growth of esophageal carcinoma xenografts. Dis Esophagus 25: 757-763, 2012.
148. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135: 1429-1435, 2009.
149. Xia CY, Zhang Z, Xue YX, Wang P, Liu YH. Mechanisms of the increase in the permeability of the blood-tumor barrier obtained by combining low-frequency ultrasound irradiation with small-dose bradykinin. J Neurooncol 94: 41-50, 2009.
150. Xu J, Xu F, Lin Y. Cigarette smoke synergizes lipopolysaccharideinduced interleukin-1beta and tumor necrosis factor-alpha secretion from macrophages via substance P-mediated nuclear factor-kappaB activation. Am J Respir Cell Mol Biol 44: 302-308, 2011.
151. Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol 31: 2856-2864, 2011.
152. Yigit B, Bozkurt N, Narter F, Yilmaz H, Yucebas E, Isbir T. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis. Anticancer Res 27: 933-936, 2007.
153. Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensinconverting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ 183: E1073-E1084, 2011.
154. Zambidis ET, Park TS, Yu W, Tam A, Levine M, Yuan X, Pryzhkova M, Peault B. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 112: 3601-3614, 2008.
155. Zhang JD, Patel MB, Song YS, Griffiths R, Burchette J, Ruiz P, Sparks MA, Yan M, Howell DN, Gomez JA, Spurney RF, Coffman TM, Crowley SD. A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res 110: 1604-1617, 2012.
156. Zhang Y, He J, Deng Y, Zhang J, Li X, Xiang Z, Huang H, Tian C, Huang J, Fan H. The insertion/deletion (I/D) polymorphism in the Angiotensin-converting enzyme gene and cancer risk: a meta-analysis. BMC Med Genet 12: 159, 2011.
157. Zhang Z, Xia C, Xue Y, Liu Y. Synergistic effect of low-frequency ultrasound and low-dose bradykinin on increasing permeability of the blood-tumor barrier by opening tight junction. J Neurosci Res 87: 2282-2289, 2009.